{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:46:09Z","timestamp":1780321569938,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018227","name":"National Research Foundation of Ukraine","doi-asserted-by":"publisher","award":["Grant# 2021.01\/0213"],"award-info":[{"award-number":["Grant# 2021.01\/0213"]}],"id":[{"id":"10.13039\/100018227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018227","name":"National Research Foundation of Ukraine","doi-asserted-by":"publisher","award":["Grant# 2021.01\/0213"],"award-info":[{"award-number":["Grant# 2021.01\/0213"]}],"id":[{"id":"10.13039\/100018227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018227","name":"National Research Foundation of Ukraine","doi-asserted-by":"publisher","award":["Grant# 2021.01\/0213"],"award-info":[{"award-number":["Grant# 2021.01\/0213"]}],"id":[{"id":"10.13039\/100018227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29757-x","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:31:28Z","timestamp":1764171088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality"],"prefix":"10.1038","volume":"15","author":[{"given":"Mykola","family":"Khalangot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliy","family":"Gurianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Zakharchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Kravchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Kovzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodymyr","family":"Shupachynskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykola","family":"Tronko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"29757_CR1","doi-asserted-by":"publisher","unstructured":"Xu, K. et al. Beneficial effects of angiotensin II receptor blockers on mortality in patients with COVID-19: A retrospective study from 2019 to 2020 in China. Cardiovasc. Drugs Ther. 11 https:\/\/doi.org\/10.1007\/s10557-023-07494-5 (2023 Aug).","DOI":"10.1007\/s10557-023-07494-5"},{"key":"29757_CR2","doi-asserted-by":"crossref","unstructured":"Hamada, S., Suzuki, T., Tokuda, Y., Taniguchi, K. & Shibuya, K. Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19. Scientific Reports, 13(1), p.11810. (2023).","DOI":"10.1038\/s41598-023-38838-8"},{"issue":"11","key":"29757_CR3","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1093\/cid\/ciaa1592","volume":"72","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. The effect of prior angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment on coronavirus disease 2019 (COVID-19) susceptibility and outcome: a systematic review and meta-analysis. Clin. Infect. Dis. 72 (11), e901\u2013e913 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"29757_CR4","doi-asserted-by":"publisher","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","volume":"4","author":"R Baral","year":"2021","unstructured":"Baral, R. et al. Association between Renin-Angiotensin-Aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and Meta-analysis. JAMA Netw. Open. 4 (3), e213594. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3594 (2021).","journal-title":"JAMA Netw. Open."},{"key":"29757_CR5","doi-asserted-by":"crossref","unstructured":"Jardine, M. J. et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ 2022;379: e072175 (2022).","DOI":"10.1136\/bmj-2022-072175"},{"key":"29757_CR6","doi-asserted-by":"publisher","first-page":"1077959","DOI":"10.3389\/fendo.2023.1077959","volume":"14","author":"M Khalangot","year":"2023","unstructured":"Khalangot, M. et al. RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives. Front. Endocrinol. (Lausanne). 14, 1077959 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"29757_CR7","doi-asserted-by":"publisher","first-page":"102484","DOI":"10.1016\/j.dsx.2022.102484","volume":"16","author":"S Harris","year":"2022","unstructured":"Harris, S. et al. Association of Statin and\/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. Diabetes Metab. Syndrome: Clin. Res. Rev. 16 (5), 102484. https:\/\/doi.org\/10.1016\/j.dsx.2022.102484 (2022).","journal-title":"Diabetes Metab. Syndrome: Clin. Res. Rev."},{"issue":"10","key":"29757_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"Barron, E. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in england: a whole-population study. Lancet Diabetes Endocrinol. 8 (10), 813\u2013822 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"29757_CR9","doi-asserted-by":"publisher","first-page":"108263","DOI":"10.1016\/j.diabres.2020.108263","volume":"165","author":"A Alkundi","year":"2020","unstructured":"Alkundi, A., Mahmoud, I., Musa, A., Naveed, S. & Alshawwaf, M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the united kingdom: A retrospective single centre study. Diabetes Res. Clin. Pract. 165, 108263. https:\/\/doi.org\/10.1016\/j.diabres.2020.108263 (2020).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"29757_CR10","doi-asserted-by":"crossref","unstructured":"Elamari, S. et al. Characteristics and outcomes of diabetic patients infected by the SARS-CoV-2. Pan African Medical Journal, 37:32. (2020).","DOI":"10.11604\/pamj.2020.37.32.25192"},{"issue":"1","key":"29757_CR11","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1002\/edm2.391","volume":"6","author":"YO Hardy","year":"2023","unstructured":"Hardy, Y. O. et al. Clinical and laboratory profile and outcomes of hospitalized COVID\u201019 patients with type 2 diabetes mellitus in Ghana\u2013A single\u2010center study. Endocrinol. Diabetes Metabolism. 6 (1), e391 (2023).","journal-title":"Endocrinol. Diabetes Metabolism"},{"key":"29757_CR12","unstructured":"STANDARDS OF MEDICAL CARE CORONAVIRUS DISEASE (COVID-19) ministry of health of Ukraine (Document in Ukrainian). Available at: https:\/\/moz.gov.ua\/uploads\/3\/19713-standarti_med_dopomogi_covid_19.pdf"},{"key":"29757_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods. 41, 1149\u20131160 (2009).","journal-title":"Behav. Res. Methods"},{"key":"29757_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0002-9343(99)00055-8","volume":"106","author":"TA Hillier","year":"1999","unstructured":"Hillier, T. A., Abbott, R. D. & Barrett, E. J. Hyponatremia: evaluating the correction factor for hyperglycemia. Am. J. Med. 106, 399\u2013403 (1999).","journal-title":"Am. J. Med."},{"key":"29757_CR15","doi-asserted-by":"crossref","unstructured":"Piarulli, F. et al. Association of COVID-19 outcomes with diabetes in the Veneto region (north-east italy): Epidemiological insights for the endemic phase? Nutrition, metabolism, and cardiovascular diseases: NMCD, 33(11), pp.2141\u20132150. (2023).","DOI":"10.1016\/j.numecd.2023.06.016"},{"key":"29757_CR16","doi-asserted-by":"crossref","unstructured":"Satman, I. et al. Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul. diabetes research and clinical practice, 174, p.108753. (2021).","DOI":"10.1016\/j.diabres.2021.108753"},{"issue":"5","key":"29757_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S2213-8587(21)00050-4","volume":"9","author":"K Khunti","year":"2021","unstructured":"Khunti, K. et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 9 (5), 293\u2013303 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"29757_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2020.11.014","volume":"33","author":"B Yu","year":"2021","unstructured":"Yu, B., Li, C., Sun, Y. & Wang, D. W. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metabol. 33 (1), 65\u201377 (2021).","journal-title":"Cell Metabol."},{"issue":"1","key":"29757_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines11010013","volume":"11","author":"PV Sodhi","year":"2023","unstructured":"Sodhi, P. V., Sidime, F., Tarazona, D. D., Valdivia, F. & Levano, K. S. A closer look at ACE2 signaling pathway and processing during COVID-19 infection: identifying possible targets. Vaccines 11 (1), 13. https:\/\/doi.org\/10.3390\/vaccines11010013 (2023).","journal-title":"Vaccines"},{"key":"29757_CR20","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1038\/s41440-024-01848-8","volume":"47","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto, S. Do angiotensin-converting enzyme inhibitors not reduce the risk of pneumonia? Hypertens. Res. 47, 2961\u20132963. https:\/\/doi.org\/10.1038\/s41440-024-01848-8 (2024).","journal-title":"Hypertens. Res."},{"key":"29757_CR21","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00228-024-03709-2","volume":"80","author":"J Fastbom","year":"2024","unstructured":"Fastbom, J. et al. Use of drugs for hypertension or heart failure and the risk of death in COVID-19: association with loop-diuretics. Eur. J. Clin. Pharmacol. 80, 1515\u20131522. https:\/\/doi.org\/10.1007\/s00228-024-03709-2 (2024).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"29757_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ehjcvp\/pvad067","volume":"10","author":"MM Lee","year":"2024","unstructured":"Lee, M. M. et al. Effects of renin\u2013angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur. Heart Journal-Cardiovascular Pharmacotherapy. 10 (1), 68\u201380 (2024).","journal-title":"Eur. Heart Journal-Cardiovascular Pharmacotherapy"},{"issue":"9","key":"29757_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/jch.14869","volume":"26","author":"V Kamalumpundi","year":"2024","unstructured":"Kamalumpundi, V. et al. Association between renin-angiotensin antagonism and COVID\u201019\u2013related mortality in patients with essential hypertension: A single center, retrospective cohort study. J. Clin. Hypertens. 26 (9), 1039\u20131044 (2024).","journal-title":"J. Clin. Hypertens."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29757-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:59:51Z","timestamp":1777129191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29757"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29757-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences ethics committee. Owing to the retrospective nature and anonymity of this study, the ethics committee of the Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences waived the need for written informed consent. Protocol # 35\/4-KE from 01\/04\/2021.\n                      Consent for publication\n                      Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"45390"}}